silybin has been researched along with carboplatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, P; Agarwal, R; Dhanalakshmi, S; Glode, LM | 1 |
| Agarwal, C; Agarwal, R; Chan, DC; Tyagi, AK | 1 |
2 other study(ies) available for silybin and carboplatin
| Article | Year |
|---|---|
Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carboplatin; Caspases; Cell Cycle; Cisplatin; Cytochrome c Group; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Immunoblotting; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Silybin; Silybum marianum; Silymarin; Tumor Cells, Cultured | 2003 |
Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
Topics: Anticarcinogenic Agents; Breast Neoplasms; Carboplatin; Cell Division; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Synergism; Female; Humans; Kinetics; Silybin; Silybum marianum; Silymarin | 2004 |